Objectives. The aim of this study was to assess the immediate and short-term results of anterograde catheter closure of a moderate-to large-sized patent ductus arteriosus (PDA) using the new self-expandable, respositionable Amplatzer duct occluder (ADO) device.
The Rashkind, buttoned, Botalloocluder devices and coils have been used extensively for transcatheter closure of a patent ductus arteriosus (PDA) with variable degrees of successful deployment and an incidence of residual shunting varying between 3% and 38% (1) (2) (3) (4) (5) (6) (7) (8) (9) . Furthermore, some of the devices require large delivery catheters, limiting their use in small infants, and the use of these devices and coils is technically challenging, especially for large PDAs. Recently, Sharafuddin et al. (10) reported on the use of a new self-expandable device (Amplatzer duct occluder [ADO] ) to close surgically created aortopulmonary shunts in a canine model with very encouraging results. In the present report, we describe the immediate and short-term results using the ADO to close moderate-to large-sized PDAs.
Methods
Patients. From September 1996 to June 1997, 24 patients (18 female, 6 male) underwent attempted transcatheter closure of a PDA as an alternative to standard surgical ligation or the use of other devices. Informed consent was obtained from all patients. All patients had clinical and echocardiographic findings of a PDA. The patients median age was 3.8 years (range 0.4 to 48), and their weights ranged from 6 to 70 kg (median 15.5 kg). All patients were asymptomatic, except for Patient 22, who had failure to thrive and pulmonary artery hypertension (mean 46 mm Hg) from the large PDA (5.7 mm). All patients had left atrial and ventricular volume overload documented by echocardiography and angiography.
ADO device. The Amplatzer duct occluder (AGA Medical Corporation, Golden Valley, MN) is a self-expandable, mushroom-shaped device made from a 0.004-in. thick Nitinol wire mesh (a thin retention disk, 4 mm larger in size than the diameter of the device ensures secure positioning in the mouth of the PDA). The PDA is closed by the induction of thrombosis, which is accomplished by polyester fibers sewn securely into the device. Platinum marker bands are applied to the wire ends and laser welded. The shape is then formed by heat treatment. After cooling, a stainless steel sleeve with a female thread is welded to the marker band using advanced laser technology, Figure 1 demonstrates the device currently under clinical evaluation with the delivery system. All devices are cone-shaped and 7 mm in length, with a recessed screw, sizes are given from the larger to the smaller diameter. The delivery system consists of a delivery cable, long Mullins-type sheath, loader and pin vise (Fig. 1) .
Closure protocol. Figure 2 demonstrates the steps of the procedure for the implantation of the ADO. All patients underwent routine right and left heart catheterization using a 4F or 5F sheath in the femoral artery and a 6F sheath in the femoral vein. Heparin was used according to operator preferences. A biplane anteroposterior and lateral descending aortogram was performed to evaluate the size, position and shape of the ductus. A 5F or 6F multipurpose catheter was advanced from the venous side into the PDA and placed in the descending aorta. This catheter was exchanged for the delivery sheath (6F) over a 0.035-in. exchange guidewire and the dilator was removed, leaving the sheath in the descending aorta.
The delivery cable was passed through the loader and the proper size occlusion device (Ն1 to 2 mm larger than the narrowest size of the PDA) was screwed clockwise into the tip of the delivery cable. The device and the loader were immersed in saline solution as the ADO was pulled into the loader. The loader was introduced into the delivery sheath and without rotation the device was advanced into the descending aorta. The sheath was retracted until the retention disk was opened in the proximal descending aorta. The sheath with the delivery cable in it were pulled back as one unit until the retention disk was snug against the aortic end of the ampulla. While maintaining tension on the delivery cable, the introducing sheath was withdrawn into the pulmonary artery to deploy the tubular frame of the prosthesis into the PDA, similar in a way to deployment of a self-expandable stent. With the device still attached to the cable, a descending aortogram was performed in the lateral projection to confirm device position. If there was device malposition, the device could be retracted back inside the delivery sheath. Once proper device position was confirmed, the device was released by turning the cable counterclockwise using the pin vise. A repeat descending aortogram Amplatzer Duct Occluder and delivery system. A, Schematic representation of the device. Note the cone shape and the various measurements; for example, for the 10-mm, 8-mm device, the distance between the two long curved arrows is 8 mm; the distance between the two short arrows is 10 mm; and the distance between the long straight arrow (retention disk) and the long curved arrow is always 7 mm for all devices. B, Closeup view of the device attached to the delivery cable by a microscrew. C, Entire delivery system with the device.
was performed 10 minutes after the release to assess the degree of residual shunt.
Within 24 h, chest radiographs in the posteroanterior and lateral positions were obtained to assess device position, and each patient underwent a complete two-dimensional echocardiographic study and color flow mapping and Doppler interrogation using commercially available machines. At 1 and 3 months after closure, repeat echocardiography looking for residual ductal flow in the main pulmonary artery, left pulmo- nary artery stenosis or aortic obstruction was performed following previously described techniques (11, 12) . Chest X-ray films in posteroanterior projections were obtained to check for wire fractures during the same follow-up examinations.
Statistical analysis. Results are expressed as mean value Ϯ SD or median and range; 95% confidence intervals were calculated for the 1-and 3-month follow-up periods.
Results
Patients. The clinical data of the 24 patients are shown in Table 1 . The mean PDA diameter was 3.7 Ϯ 1.5 mm, and the median pulmonary/systemic flow ratio (Q p /Q s ) was 2.2 (range 1.6 to 11). According to the classification adopted by Krichenko et al. (13) , 22 patients had PDA type A, and 2 had type E. All closures were achieved from the venous side. In 23 patients the device was placed successfully in the PDA. One patient (Patient 7), a 9-kg infant with a PDA measuring 1.2 mm at its narrowest point with a short ampulla, initially underwent an attempt at deploying a device 6 -4 mm in diameter and 10 mm in length. Deploying the retention disk in the aortic end resulted in obstruction of more than half the aorta. Therefore, the device was retracted inside the delivery sheath; placement of a coil resulted in complete closure. Subsequent to this patient, all devices were modified to make their length shorter (7 mm), and the screw was recessed inside the disk (Fig. 1) . Eight patients had immediate angiographic closure of the PDA, including the single patient who received a coil; 14 patients had trace angiographic residual shunt (7) with "foaming" through the device and no contrast jet; and 2 patients had small residual shunt with a contrast jet through the device. One patient (Patient 22) with significant pulmonary artery hypertension (mean 46 mm Hg) had immediate improvement, with reduction of the pulmonary artery mean pressure to 24 mm Hg. The median fluoroscopy time was 13.5 min (range 6.3 to 47), and the median total procedure time was 60 min (range 36 to 185). The longest fluoroscopy and procedure times were in two patients (Patients 2 and 11). Patient 2 underwent the procedure during our early learning experience; in Patient 11, both the retention disk and the tubular part of the device were deployed inside the PDA, with some difficulty in repositioning the device precisely. There were no complications during or after the procedure.
There was no evidence of obstruction of the left pulmonary artery or the descending aorta confirmed on the following day and on follow-up by Doppler interrogation. No patient required blood transfusion. There were no femoral arterial or venous complications. All patients were discharged home the day after the catheterization procedure. Figure 1 for device size measurement. C ϭ closure; Coil ϭ procedure failed for device implantation, a coil was implanted instead; Diam ϭ diameter; FT ϭ fluoroscopy time; Immed ϭ immediately at the end of procedure; NA ϭ not available; PDA ϭ patent ductus arteriosus; PT ϭ procedure time; Pt ϭ patient; Q p /Q s ϭ pulmonary/systemic flow ratio; SS ϭ small shunt; TS ϭ trace shunt by angiography (7).
Follow-up.
At 24 h, all 23 patients had complete closure of their PDAs on color Doppler echocardiography. Of the 23 patients, 21 completed the 1-month follow-up period, all (95% confidence interval [CI] 86% to 100%) with complete closure, and 18 of 23 patients completed the 3-month follow-up, all (95% CI 83% to 100%) with complete closure and no evidence of device migration, recanalization, thromboembolic episodes, endocarditis, wire fracture or clinical evidence of hemolysis.
Discussion
The feasibility of nonsurgical closure of the PDA was demonstrated when Porstmann et al. (14) in 1967 reported closing a PDA with an Ivalon plug in a 17-year old boy without thoracotomy. Subsequently, a number of devices and coils have been used for catheter closure of PDA with varying degrees of success (1-9). The major drawbacks of these devices and coils are the high incidence of residual shunt, the sometimes complex delivery systems and their unsuitability for larger PDAs.
In this study, we report our initial human experience using a different new device to close PDAs Յ6 mm in diameter. We performed the closures from the venous side in all patients, using 6F catheters. The venous route has several advantages, including confirmation of PDA position before device release because the arterial catheter can be used for injection of contrast, avoidance of a large sheath in the femoral artery and the potential application of this technique to the very young infant who has PDA. Although we did not encounter all the angiographic types of PDA, we believe that such PDAs will be easily amenable to closure with this device. Further clinical testing is necessary to determine any potential size and angiographic shape limitations of this device. Although most patients had a residual shunt at the end of the procedure, none had a detectable residual shunt by color flow mapping within 24 h of implantation, stressing the advantage of the plug type of design of the device for closing PDAs. Although most procedures were performed under anesthesia and patients were admitted to the hospital for one night, we believe that because of the small size sheath, the closure can be safely performed as an outpatient procedure under local anesthesia and heavy sedation. On the basis of our preliminary work, the devices will be available in a kit that contains three different sizes (10 -8, 8 -6 and 6 -4 mm) to cover the whole range of PDA sizes.
Conclusions. The ADO is safe and effective in closing PDAs in most patients with a PDA Յ6 mm in diameter. Further clinical trials are underway to assess any potential size or shape limitations before the widespread use of this device.
